×
About 4,065 results

ALLMedicine™ Hepatic Encephalopathy Center

Research & Reviews  1,408 results

Positive GABAA receptor modulating steroids and their antagonists: Implications for cli...
https://doi.org/10.1111/jne.13013
Journal of Neuroendocrinology; Bäckström T, Das R et. al.

Aug 3rd, 2021 - GABA is the main inhibitory neurotransmitter in the brain and GABAergic transmission has been shown to be of importance for regulation of mood, memory and food intake. The progesterone metabolite allopregnanolone (Allo) is a positive GABAA recepto...

History of Hepatic Encephalopathy Is Not a Contraindication to Transjugular Intrahepati...
https://doi.org/10.14309/ctg.0000000000000378
Clinical and Translational Gastroenterology; Saab S, Zhao M et. al.

Aug 2nd, 2021 - The outcomes of transjugular intrahepatic portosystemic shunt (TIPS) placement in patients with hepatic encephalopathy (HE) are controversial. We studied the relationship of pre-TIPS HE in patients undergoing TIPS for refractory ascites on all-cau...

Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in pat...
https://doi.org/10.1002/jpen.2222
JPEN. Journal of ParEnteral and Enteral Nutrition; Miwa T, Hanai T et. al.

Jul 22nd, 2021 - Handgrip strength (HGS) is a simple and convenient method to assess nutritional status in patients with cirrhosis. This retrospective study aimed to investigate the utility of HGS for predicting patients with covert hepatic encephalopathy (CHE) an...

North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystem...
https://doi.org/10.1016/j.cgh.2021.07.018
Clinical Gastroenterology and Hepatology : the Official C... Boike JR, Thornburg BG et. al.

Jul 19th, 2021 - Complications of portal hypertension, including ascites, gastrointestinal bleeding, hepatic hydrothorax, and hepatic encephalopathy are associated with significant morbidity and mortality. Despite few high quality randomized controlled trials to g...

Normalisation of the psychometric encephalopathy score within the Cameroonian population.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273953
BMC Gastroenterology; Pessidjo Djomatcho L, Kowo MP et. al.

Jul 13th, 2021 - Minimal hepatic encephalopathy (MHE) is the presence of neuropsychological abnormalities detectable by psychometric tests. Psychometric Hepatic Encephalopathy Score (PHES) is a gold standard test for the early diagnosis of MHE in cirrhotic patient...

see more →

Guidelines  5 results

KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy,...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160350
Clinical and Molecular Hepatology;

Jan 11th, 2020 - KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.|2020| ,|

Chinese guidelines on management of hepatic encephalopathy in cirrhosis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767982
World Journal of Gastroenterology; Xu XY, Ding HG et. al.

Oct 3rd, 2019 - The Chinese Society of Hepatology developed the current guidelines on the management of hepatic encephalopathy in cirrhosis based on the published evidence and the panelists' consensus. The guidelines provided recommendations for the diagnosis and...

Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediat...
https://doi.org/10.1016/j.bbmt.2017.08.035
Biology of Blood and Marrow Transplantation : Journal of ... Ovchinsky N, Frazier W et. al.

Sep 6th, 2017 - Some patients with veno-occlusive disease (VOD) have multiorgan dysfunction, and multiple teams are involved in their daily care in the pediatric intensive care unit. Cardiorespiratory dysfunction is critical in these patients, requiring immediate...

How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885589
European Journal of Gastroenterology & Hepatology; Shawcross DL, Dunk AA et. al.

Nov 26th, 2015 - Hepatic encephalopathy is defined as brain dysfunction caused by liver insufficiency and/or portosystemic shunting. Symptoms include nonspecific cognitive impairment, personality changes and changes in consciousness. Overt (symptomatic) hepatic en...

Review article: the design of clinical trials in hepatic encephalopathy--an Internation...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971432
Alimentary Pharmacology & Therapeutics; Bajaj JS, Cordoba J et. al.

Feb 11th, 2011 - The clinical classification of hepatic encephalopathy is largely subjective, which has led to difficulties in designing trials in this field. To review the current classification of hepatic encephalopathy and to develop consensus guidelines on the...

see more →

Drugs  22 results see all →

Clinicaltrials.gov  91 results

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
https://clinicaltrials.gov/ct2/show/NCT03712280

May 7th, 2020 - The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.

Oral Microbiome of Patients With Hepatitis C Virus Infection
https://clinicaltrials.gov/ct2/show/NCT03682549

Apr 24th, 2020 - Human oral cavity is a great habitat for more than 600 species of bacteria, known as oral microbiota, living in equilibrium. Oral microbiota plays an important role in maintaining oral health; however when the balance in oral bacterial population ...

Hepatic Urea Nitrogen Handling in Patients With NASH
https://clinicaltrials.gov/ct2/show/NCT03260036

Mar 30th, 2020 - NAFLD is the most common cause of chronic liver disease in the western world affecting 10-30% of the general population. It is strongly associated with the metabolic syndrome caused by overweight and obesity. NAFLD is a spectrum of liver disease r...

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
https://clinicaltrials.gov/ct2/show/NCT03702920

Mar 20th, 2020 - Approximately 380 subjects with cirrhosis, ACLF, and high risk of hospital mortality (ACLF-1b, ACLF-2, or ACLF-3a) will be included in this study after obtaining written informed consent. In case of hepatic encephalopathy (HE), written informed co...

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03663114

Feb 6th, 2020 - This study is a post-marketing observational study of lenvatinib in participants with unresectable hepatocellular carcinoma. The primary objective of this study is assessment of risk factors for hepatic encephalopathy.

see more →

News  99 results

Rifaximin May Prevent Hepatic Encephalopathy After TIPS Placement for Cirrhosis
https://www.medscape.com/viewarticle/945312

Feb 5th, 2021 - NEW YORK (Reuters Health) - The antibiotic rifaximin given before and after transjugular intrahepatic portosystemic shunt (TIPS) placement helped prevent hepatic encephalopathy (HE) in a placebo-controlled trial. "TIPS is a very effective treatmen...

Sarcopenia Does Not Worsen Survival After Shunting for Refractory Ascites
https://www.medscape.com/viewarticle/939918

Oct 29th, 2020 - NEW YORK (Reuters Health) - In patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites, sarcopenia is not associated with increased mortality, according to new research from the UK. "Until now...

Tools Emerging to Predict Liver Failure in Cirrhosis
https://www.staging.medscape.com/viewarticle/937030

Sep 8th, 2020 - Systemic inflammation and portal hypertension are key predictors of acute-on-chronic liver failure (ACLF) in the 3 months after a hospital stay for acute decompensated cirrhosis and also of death after 12 months, a preliminary analysis of data fro...

Belapectin misses endpoints in NASH trial
https://www.mdedge.com/gihepnews/article/218838/hepatology/belapectin-misses-endpoints-nash-trial?channel=346
Amy Karon, MDedge News

Mar 11th, 2020 - For patients with nonalcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension, belapectin therapy was safe but did not significantly improve fibrosis or hepatic venous pressure gradient, compared with placebo, according to the resul.

Inner demons
https://www.mdedge.com/gihepnews/article/212611/mixed-topics/inner-demons?channel=41022

Dec 1st, 2019 - Julia Brennan sings about inner demons. They just won’t go away and they don’t play fair with angels.

see more →

Patient Education  1 results see all →